Injectable opioid agonist therapy, extended-release agonists, and antagonists are beyond the scope of this guideline. "The management of opioid use disorder is a rapidly changing and ever-evolving ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...

and willingness to continue opioid therapy. A literature search identified more than a dozen published reports on the use of pure opioid antagonists (naloxone, naltrexone, methylnaltrexone ...

App users also stayed with their opioid agonist therapy an average 290 days, compared with 236 days for those who only got medication, the study says. “These results are promising, and they ...

Federal officials approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioid​ medications like Vicodin and OxyContin.

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

The research, led by medical anthropologist Jennifer Carroll, found that only 7 of 94 identified residential treatment providers in North Carolina offer Opioid Agonist Treatment (OAT)—a proven ...

who may not have been successful with treatment or other addiction therapies such as oral opioid agonist therapy (OAT) and other appropriate empirically supported services. The project will identify ...